A global initiative is set to leverage oncology expertise to advance a pipeline of novel cancer therapies. Biopharmaceutical company UCB has announced a new multi-project alliance with Cancer Research UK and its innovation arm, Cancer Research Horizons. Under the new partnership, Cancer Research UK’s Centre… Read More
The National Institute for Health and Care Excellence (NICE) has recommended Rystiggo (rozanolixizumab) as a treatment for adults with antibody-positive generalised myasthenia gravis (gMG). Rystiggo is the first targeted therapy for gMG, a rare, chronic autoimmune neuromuscular disease. The condition is characterised by fluctuating muscle weakness and fatigue and can lead to difficulties with vision,… Read More
UCB has entered into a definitive agreement to acquire Neurona Therapeutics, including lead asset NRTX-1001, adding to its epilepsy portfolio. Neurona Therapeutics is a clinical-stage biotherapeutics company focused on advancing regenerative cell therapies for epilepsies and other disorders of the nervous system. UCB will pay… Read More
UCB’s Kygevvi (doxecitine and doxribtimine) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending marketing authorisation under exceptional circumstances. The recommendation is for the treatment of paediatric and adult patients with genetically confirmed thymidine kinase… Read More
Global biopharmaceutical company UCB has reported positive data for its Phase III GEMZ study which is investigating adjunctive fenfluramine in children and adults with CDKL5 Deficiency Disorder (CDD). The data were announced at the American Epilepsy Society (AES) meeting, Atlanta, USA. The results… Read More
Dox – comprising of doxecitine and doxribtimine – to treat thymidine kinase 2 deficiency (TK2d) has been granted Promising Innovative Medicine (PIM) designation in the UK by the Medicines and Healthcare Products Regulatory Agency (MHRA). TK2d is caused by a genetic mutation in the TK2 gene. This… Read More
UCB has reported encouraging Phase IIa data from the TOGETHER (AH0003) study, investigating bepranemab, an anti-tau antibody targeting the mid-region of the tau protein in people living with prodromal to mild Alzheimer’s disease. The results were presented during a late-breaking symposium at the 2024 Clinical Trials… Read More
A new clinical trial has launched to assess monoclonal antibody UCB4594 in people with advanced cancers. The first site for the study has opened at the National Institute for Health and Care Research (NIHR) Manchester Clinical Research Facility (CRF) at The Christie NHS Foundation Trust (The… Read More
UCB has revealed new data demonstrating a 55% improvement in adults with moderate to severe hidradenitis suppurativa (HS) treated with monoclonal antibody bimekizumab. The data were presented at the 13th Conference of the European Hidradenitis Suppurativa Foundation (EHSF) in Lyon, France (7-9 February). Emmanuel… Read More
Cancer Research UK and UCB have agreed a clinical development collaboration to advance two of UCB’s investigational oncology antibody candidates through clinical trials. The collaboration focuses on the development of two investigational antibody candidates, UCB6114 and UCB4594, by bringing together the oncology-focused translational research and clinical… Read More
UCB’s Fintepla (fenfluramine) oral solution has been approved in the European Union (EU) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS). It has received authorisation as an add-on therapy to other anti-epileptic medicines for patients two years of age and older. The approval… Read More
